Overview

Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium

Status:
Completed
Trial end date:
2019-07-19
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium in uncontrolled moderate to severe asthmatic patients. The planned duration of treatment in this study was 24 weeks, followed up by a 7-day follow-up period.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fluticasone
Salmeterol Xinafoate
Tiotropium Bromide